A 61-Year-Old Woman With Hepatocellular Carcinoma

Pierre Gholam, MD, reviews significant clinical trial data and treatment options for the management of unresectable HCC.

EP. 1: 61-Year-Old Female With Unresectable HCC

July 28th 2021

Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).

EP. 2: Unresectable HCC: Case Prognosis and Impressions

July 28th 2021

Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.

EP. 3: First-Line Treatment in Unresectable HCC

July 28th 2021

An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.

EP. 4: REFLECT Trial: Study Design and Key Data

July 28th 2021

Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.

EP. 5: IMbrave 150 Trial: Safety and Efficacy Data

July 28th 2021

Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.

EP. 6: Unresectable HCC: Unmet Treatment Needs

July 28th 2021

Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.

EP. 7: Unresectable HCC: Key Treatment Considerations

July 28th 2021

A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC.